Other Programs
We have three other compounds, Inhaled CISPLATIN Lipid Complex, rhIGFBP-3 and INSM-18, in early development.
Inhaled CISPLATIN Lipid Complex is a novel sustained-release formulation of CISPLATIN in a lipid-based complex designed specifically for administration via inhalation for cancers affecting the lung. The compound was studied in three separate phase 1 clinical studies - patients who have lung metastasis due to recurrent osteosarcoma, patients who have broncho-alveolar carcinoma of the lung and patients with end-stage non-small cell lung cancer.The compound is currently in pre-clinical development, and we have out-licensed the rights to Eleison Pharmaceuticals Inc., a privately held company focused on developing compounds for orphan indications.
Preclinical models demonstrate that both rhIGFBP-3 and INSM-18 interact with the IGF system to reduce tumor growth. We are not actively pursuing the development of either of these products at this time and have out licensed the rights of INSM-18 to Napo Pharmaceuticals, Inc., for diabetes and to TriAct Therapeutics Inc. for other INSM -18 indications. Due to the high cost of trials in the oncology area, we would need to identify a partner to co-develop rhIGFBP-3.
